clinical trial · NCT07464314
A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
GlaxoSmithKline·phase1·recruiting·n = 225
Influenza, Human+COVID-19Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) VaccineLicensed Seasonal Influenza VaccineLicensed COVID-19 Vaccine
brief summary
This early-stage study will look at a new mRNA vaccine that combines defenses against both seasonal flu and COVID-19 in terms of its safety and how it builds protection. Healthy adults aged 65 to 85 will receive different doses of this new vaccine, a standard flu vaccine, or COVID-19 vaccine. The study will assess any side effects or health issues, and additional blood samples will be collected at specific times to evaluate how well participants bodies build protection against the flu and COVID-19.
started
Mar 9, 2026
primary completion
Dec 3, 2026
completion
Jun 3, 2027
last updated
Mar 27, 2026
official title
A Phase 1, Observer-Blind, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of an Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol